EpiPen Controversy: Mylan CEO Faces Congressional Committee
September 22, 2016
Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.
In her pre-released testimony, Bresch attempted to clarify exactly how much money Mylan makes off each EpiPen sale.
For the rest of this news release, see Pharmaceutical Technology.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
